181 related articles for article (PubMed ID: 21929800)
41. Clinical outcome of Turkish metastatic breast cancer patients with currently available treatment modalities--single center experience.
Cabuk D; Basaran G; Teomete M; Dane F; Korkmaz T; Seber S; Telli F; Yumuk PF; Turhal S
Asian Pac J Cancer Prev; 2014; 15(1):117-22. PubMed ID: 24528011
[TBL] [Abstract][Full Text] [Related]
42. 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial.
Pivot X; Romieu G; Debled M; Pierga JY; Kerbrat P; Bachelot T; Lortholary A; Espié M; Fumoleau P; Serin D; Jacquin JP; Jouannaud C; Rios M; Abadie-Lacourtoisie S; Tubiana-Mathieu N; Cany L; Catala S; Khayat D; Pauporté I; Kramar A;
Lancet Oncol; 2013 Jul; 14(8):741-8. PubMed ID: 23764181
[TBL] [Abstract][Full Text] [Related]
43. Association between the HER2 Ile655Val polymorphism and response to trastuzumab in women with operable primary breast cancer.
Han X; Diao L; Xu Y; Xue W; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
Ann Oncol; 2014 Jun; 25(6):1158-64. PubMed ID: 24608202
[TBL] [Abstract][Full Text] [Related]
44. Correlation between quantitative HER-2 protein expression and risk for brain metastases in HER-2+ advanced breast cancer patients receiving trastuzumab-containing therapy.
Duchnowska R; Biernat W; Szostakiewicz B; Sperinde J; Piette F; Haddad M; Paquet A; Lie Y; Czartoryska-Arłukowicz B; Wysocki P; Jankowski T; Radecka B; Foszczynska-Kłoda M; Litwiniuk M; Debska S; Weidler J; Huang W; Buyse M; Bates M; Jassem J
Oncologist; 2012; 17(1):26-35. PubMed ID: 22234627
[TBL] [Abstract][Full Text] [Related]
45. High plasma fibrinogen is correlated with poor response to trastuzumab treatment in HER2 positive breast cancer.
Liu YL; Lu Q; Liang JW; Xia Y; Zhang W; Hu BQ; Shang FF; Ji YR; Wang J; Wang Q; Liang B
Medicine (Baltimore); 2015 Feb; 94(5):e481. PubMed ID: 25654390
[TBL] [Abstract][Full Text] [Related]
46. Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases.
Jacot W; Pons E; Frenel JS; Guiu S; Levy C; Heudel PE; Bachelot T; D'Hondt V; Darlix A; Firmin N; Romieu G; Thezenas S; Dalenc F
Breast Cancer Res Treat; 2016 Jun; 157(2):307-318. PubMed ID: 27167986
[TBL] [Abstract][Full Text] [Related]
47. [Brain metastases in breast cancer: a special disease course for HER2 positive tumors].
Hurkens KP; Hupperets PS; Creemers GJ; Erdkamp FL; van de Vijver KK; Tjan-Heijnen VC
Ned Tijdschr Geneeskd; 2008 Dec; 152(50):2701-6. PubMed ID: 19192581
[TBL] [Abstract][Full Text] [Related]
48. Trastuzumab treatment improves brain metastasis outcomes through control and durable prolongation of systemic extracranial disease in HER2-overexpressing breast cancer patients.
Park YH; Park MJ; Ji SH; Yi SY; Lim DH; Nam DH; Lee JI; Park W; Choi DH; Huh SJ; Ahn JS; Kang WK; Park K; Im YH
Br J Cancer; 2009 Mar; 100(6):894-900. PubMed ID: 19240719
[TBL] [Abstract][Full Text] [Related]
49. Central nervous system metastases in a cohort of metastatic breast cancer patients treated with trastuzumab.
Montagna E; Cancello G; D'Agostino D; Lauria R; Forestieri V; Esposito A; Silvestro L; Accurso A; De Placido S; De Laurentiis M
Cancer Chemother Pharmacol; 2009 Jan; 63(2):275-80. PubMed ID: 18379783
[TBL] [Abstract][Full Text] [Related]
50. Time to first tumor progression as outcome predictor of a second trasuzumab-based therapy beyond progression in HER-2 positive metastatic breast cancer.
Metro G; Giannarelli D; Gemma D; Lanzetta G; Ciccarese M; Papaldo P; Gamucci T; Lorusso V; Mottolese M; Magnolfi E; Cognetti F; Fabi A
Breast J; 2010; 16(1):66-72. PubMed ID: 19889170
[TBL] [Abstract][Full Text] [Related]
51. Incidence, pattern and timing of brain metastases among patients with advanced breast cancer treated with trastuzumab.
Yau T; Swanton C; Chua S; Sue A; Walsh G; Rostom A; Johnston SR; O'Brien ME; Smith IE
Acta Oncol; 2006; 45(2):196-201. PubMed ID: 16546866
[TBL] [Abstract][Full Text] [Related]
52. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review.
Dawood S; Broglio K; Buzdar AU; Hortobagyi GN; Giordano SH
J Clin Oncol; 2010 Jan; 28(1):92-8. PubMed ID: 19933921
[TBL] [Abstract][Full Text] [Related]
53. Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial.
Cortés J; Dieras V; Ro J; Barriere J; Bachelot T; Hurvitz S; Le Rhun E; Espié M; Kim SB; Schneeweiss A; Sohn JH; Nabholtz JM; Kellokumpu-Lehtinen PL; Taguchi J; Piacentini F; Ciruelos E; Bono P; Ould-Kaci M; Roux F; Joensuu H
Lancet Oncol; 2015 Dec; 16(16):1700-10. PubMed ID: 26596672
[TBL] [Abstract][Full Text] [Related]
54. Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases.
Leyland-Jones B
J Clin Oncol; 2009 Nov; 27(31):5278-86. PubMed ID: 19770385
[TBL] [Abstract][Full Text] [Related]
55. Long-term tumor remission under trastuzumab treatment for HER2 positive metastatic breast cancer - results from the HER-OS patient registry.
Witzel I; Müller V; Abenhardt W; Kaufmann M; Schoenegg W; Schneeweis A; Jänicke F
BMC Cancer; 2014 Nov; 14():806. PubMed ID: 25371387
[TBL] [Abstract][Full Text] [Related]
56. Treatment patterns and clinical outcomes in elderly patients with HER2-positive metastatic breast cancer from the registHER observational study.
Kaufman PA; Brufsky AM; Mayer M; Rugo HS; Tripathy D; Yood MU; Feng S; Wang LI; Quah CS; Yardley DA
Breast Cancer Res Treat; 2012 Oct; 135(3):875-83. PubMed ID: 22923238
[TBL] [Abstract][Full Text] [Related]
57. Stereotactic radiosurgery with concurrent lapatinib is associated with improved local control for HER2-positive breast cancer brain metastases.
Parsai S; Miller JA; Juloori A; Chao ST; Kotecha R; Mohammadi AM; Ahluwalia MS; Murphy ES; Barnett GH; Vogelbaum MA; Angelov L; Peereboom DM; Suh JH
J Neurosurg; 2019 Feb; 132(2):503-511. PubMed ID: 30738402
[TBL] [Abstract][Full Text] [Related]
58. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.
Hurvitz SA; Andre F; Jiang Z; Shao Z; Mano MS; Neciosup SP; Tseng LM; Zhang Q; Shen K; Liu D; Dreosti LM; Burris HA; Toi M; Buyse ME; Cabaribere D; Lindsay MA; Rao S; Pacaud LB; Taran T; Slamon D
Lancet Oncol; 2015 Jul; 16(7):816-29. PubMed ID: 26092818
[TBL] [Abstract][Full Text] [Related]
59. Diabetes as a prognostic factor in HER-2 positive breast cancer patients treated with targeted therapy.
Lee A; Jo S; Lee C; Shin HH; Kim TH; Ahn KJ; Park SK; Cho H; Yoon HK; Kim WG; Park J; Choi Y
Breast Cancer; 2019 Sep; 26(5):672-680. PubMed ID: 30927244
[TBL] [Abstract][Full Text] [Related]
60. Central nervous system metastases in HER-2 positive metastatic breast cancer patients treated with trastuzumab: incidence, survival, and risk factors.
Gori S; Rimondini S; De Angelis V; Colozza M; Bisagni G; Moretti G; Sidoni A; Basurto C; Aristei C; Anastasi P; Crinò L
Oncologist; 2007 Jul; 12(7):766-73. PubMed ID: 17673608
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]